Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 1/20 | 0.43 |
| ▸ | JAK2 | O60674 | 9/20 | 0.40 |
| ▸ | JAK1 | P23458 | 9/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18669351 | 0.88 | MEN1 (0.44) | MEN1ALDH1A1MAPTKMT2AUSP2 | |
| SCHEMBL15171022 | 0.85 | MEN1 (0.41) | MEN1ALDH1A1MAPTKMT2AUSP2 | |
| SCHEMBL2202517 | 0.84 | GPR119 (0.36) | MEN1ALDH1A1MAPTKMT2AJAK2 | |
| SCHEMBL22958842 | 0.82 | PKM (0.45) | MEN1ALDH1A1MAPTKMT2AUSP2 | |
| SCHEMBL2204005 | 0.81 | USP2 (0.49) | MAPTUSP2SMN1; SMN2GPR119HPGD | |
| SCHEMBL19331856 | 0.81 | ALDH1A1 (0.40) | MEN1ALDH1A1MAPTKMT2AUSP2 | |
| SCHEMBL16987073 | 0.81 | JAK2 (0.44) | MEN1ALDH1A1MAPTKMT2AUSP2 | |
| SCHEMBL345355 | 0.81 | JAK2 (0.44) | MEN1ALDH1A1MAPTKMT2AUSP2 | |
| SCHEMBL2142330 | 0.81 | JAK2 (0.45) | MEN1ALDH1A1MAPTKMT2AUSP2 | |
| SCHEMBL2025632 | 0.80 | MEN1 (0.41) | MEN1ALDH1A1MAPTKMT2AUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8278319-B2 | Substituted spiroamine compounds | GRUENENTHAL GMBH (DE) | 2012-10-02 | — | — | US | disclosed |
| EP-2344457-A1 | SUBSTITUTED SPIROAMINES | Grünenthal GmbH (DE) | 2011-07-20 | — | — | EP | disclosed |
| US-20100113417-A1 | Substituted Spiroamine Compounds | GRUENENTHAL GMBH (DE) | 2010-05-06 | — | — | US | disclosed |
| WO-2010049146-A1 | SUBSTITUTED SPIROAMINES | Grünenthal GmbH (DE) | 2010-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113417-A1 | Substituted Spiroamine Compounds | BDKRB1, BDKRB2, REN | MEN1 346/4885ALDH1A1 1709/4885MAPT 2995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.